Selective androgen receptor modulators as function promoting therapies

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 12, Issue 3, 2009, Pages 232-240

  Bhasin, Shalender ^a,b   Jasuja, Ravi ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

Androgens; Mechanisms of androgen action; Mechanisms of tissue selectivity; SARMs

Indexed keywords

1 ALPHA 19 NORTESTOSTERONE; ANDROGEN; ANILINE; ANILINE DERIVATIVE; ARYLPROPIONAMIDE; AZASTEROID; BENIZIMIDAZOLE; BICYCLIC HYDANTOIN; BMS 564929; DIHYDRONANDROLONE; ESTROGEN; HYDANTOIN DERIVATIVE; IMIDAZOLE DERIVATIVE; IMIDAZOLOPYRAZOLE; INDOLE; LGD 2226; LGD 2941; MEGESTROL ACETATE; METHYLTESTOSTERONE; NANDROLONE; NANDROLONE DERIVATIVE; OXANDROLONE; PROPIONAMIDE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; S 40503; SELECTIVE ANDROGEN RECEPTOR MODULATOR; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE; TETRAHYDROQUINOLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANDROGEN RECEPTOR; ANTIANDROGEN; DRUG DERIVATIVE; LIGAND;

AGING; AROMATIZATION; BINDING AFFINITY; BIOSYNTHESIS; BONE METABOLISM; BONE REMODELING; CACHEXIA; CANCER CACHEXIA; CHRONIC DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TARGETING; ESTERIFICATION; ESTROGEN ACTIVITY; EVOLUTION; FUNCTIONAL STATUS; HORMONE SUBSTITUTION; HUMAN; HYDROPHOBICITY; NEOPLASM; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PROSTATE; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; STEROIDOGENESIS; STRUCTURE ACTIVITY RELATION; ANIMAL; DRUG DESIGN; DRUG EFFECT; MALE; METABOLISM;

RODENTIA;

ANDROGEN ANTAGONISTS; ANIMALS; DRUG DESIGN; HUMANS; LIGANDS; MALE; MUSCLE, SKELETAL; RECEPTORS, ANDROGEN; STRUCTURE-ACTIVITY RELATIONSHIP; TESTOSTERONE;

EID: 65549087111     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0b013e32832a3d79     Document Type: Review

References (69)

1. Bhasin S, Calof OM, Storer TW, et al. Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2006; 2:146-159.
2. Narayanan R, Mohler ML, Bohl CE, et al. Selective androgen receptor modulators in preclinical and clinical development. Nuclear receptor signaling 2008; 6:e010. An excellent treatise of SARM chemistry and structure-activity relationships.
3. Edwards JP, West SJ, Pooley CL, et al. New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone. Bioorg Med Chem Lett 1998; 8:745-750.
4. Hamann LG, Mani NS, Davis RL, et al. Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl)-8-pyridono[5,6-g]- quinoline (LG121071). J Med Chem 1999; 42:210-212.
5. Miner JN, Chang W, Chapman MS, et al. An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology 2007; 148:363-373.
6. Negro-Vilar A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab 1999; 84:3459-3462.
7. Dalton JT, Mukherjee A, Zhu Z, et al. Discovery of nonsteroidal androgens. Biochem Biophys Res Commun 1998; 244:1-4.
8. He Y, Yin D, Perera M, et al. Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor. Eur J Med Chem 2002; 37:619-634.
9. Higuchi RI, Arienti KL, Lopez FJ, et al. Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. J Med Chem 2007; 50:2486-2496.
10. Martinborough E, Shen Y, Oeveren A, et al. Substituted 6-(1-pyrrolidine)quinolin-2(1H)-ones as novel selective androgen receptor modulators. J Med Chem 2007; 50:5049-5052.
11. Rosen J, Negro-Vilar A. Novel, nonsteroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile. J Musculoskelet Neuronal Interact 2002; 2:222-224.
12. van Oeveren A, Motamedi M, Mani NS, et al. Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator. J Med Chem 2006; 49:6143-6146.
13. van Oeveren A, Motamedi M, Martinborough E, et al. Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones. Bioorg Med Chem Lett 2007; 17:1527-1531.
14. Bhasin S. Testicular Disorders. In: Larsen R, Kronenberg H, Melmed S, Polonski K, editors. Williams' Textbook of Endocrinology. Philadelphia, PA: WB Saunders, Inc.; 2007.
15. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91:1995-2010.
16. Baumgartner RN. Body composition in healthy aging. Ann N Y Acad Sci 2000; 904:437-448.
17. Baumgartner RN, Waters DL, Gallagher D, et al. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 1999; 107:123-136.
18. Roy TA, Blackman MR, Harman SM, et al. Interrelationships of serum testosterone and free testosterone index with FFM and strength in aging men. Am J Physiol Endocrinol Metab 2002; 283:E284-E294.
19. Melton LJ 3rd, Khosla S, Crowson CS, et al. Epidemiology of sarcopenia. J Am Geriatr Soc 2000; 48:625-630.
20. Bassey EJ, Fiatarone MA,O'Neill EF, et al. Leg extensor power and functional performance in very old men and women. Clin Sci (Lond) 1992; 82:321-327.
21. Lexell J, Downham D, Sjostrom M. Distribution of different fibre types in human skeletal muscles. A statistical and computational study of the fibre type arrangement in m. vastus lateralis of young, healthy males. J Neurol Sci 1984; 65:353-365.
22. Orwoll E, Lambert LC, Marshall LM, et al. Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med 2006; 166:2124-2131.
23. Bhasin S, Storer TW, Berman N, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82:407-413.
24. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (Andro-Gel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004; 89:2085-2098.
25. Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000; 85:2839-2853.
26. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85:2670-2677.
27. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335:1-7.
28. Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001; 281:E1172-E1181.
29. Bhasin S, Woodhouse L, Casaburi R, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 2005; 90:678-688.
30. Casaburi R, Bhasin S, Cosentino L, et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:870-878.
31. Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA 1999; 281:1275-1281.
32. Woodhouse LJ, Reisz-Porszasz S, Javanbakht M, et al. Development of models to predict anabolic response to testosterone administration in healthy young men. Am J Physiol Endocrinol Metab 2003; 284:E1009-E1017.
33. Storer TW, Magliano L, Woodhouse L, et al. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab 2003; 88:1478-1485.
34. Calof O, Singh AB, Lee ML, et al. Adverse events associated with testosterone supplementation of odler men. J Gerontol A Biol Sci Med Sci 2005; 60:1451-1457.
35. Yin D, He Y, Perera MA, et al. Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol Pharmacol 2003; 63:211-223.
36. Yin D, Gao W, Kearbey JD, et al. Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther 2003; 304:1334-1340.
37. Gao W, Kearbey JD, Nair VA, et al. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Endocrinology 2004; 145:5420-5428.
38. Gao W, Reiser PJ, Coss CC, Phelps MA, Kearbey JD, Miller DD, Dalton JT. Selective Androgen Receptor Modulator (SARM) Treatment Improves Muscle Strength and Body Composition, and Prevents Bone Loss in Orchidectomized Rats. Endocrinology 2005.
39. Gao W, Reiser PJ, Coss CC, et al. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology 2005; 146:4887-4897.
40. Gao W, Reiser PJ, Kearbey JD, et al. Effects of novel selective androgen receptor modulator (SARM) on skeletal muscle mass and strength in castrated male rats. New Orleans: The Endocrine Society; 2004.
41. Kearbey JD, Gao W, Narayanan R, et al. Selective androgen receptor modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharmaceutical research 2007; 24:328-335.
42. Bohl CE, Gao W, Miller DD, et al. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A 2005; 102:6201-6206. An important paper that describes the structural basis of antagonism of bicalutamide based on the crystal structure.
43. Hamann LG, Manfredi MC, Sun C, et al. Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators. Bioorg Med Chem Lett 2007; 17:1860-1864.
44. Manfredi MC, Bi Y, Nirschl AA, et al. Synthesis and SAR of tetrahydropyrrolo[1,2-b][1,2,5]thiadiazol-2(3H)-one 1,1-dioxide analogues as highly potent selective androgen receptor modulators. Bioorg Med Chem Lett 2007; 17:4487-4490.
45. Ostrowski J, Kuhns JE, Lupisella JA, et al. Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology 2007; 148:4-12.
46. Kim J, Wu D, Hwang DJ, et al. The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-prop ionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators. J Pharmacol Exp Ther 2005; 315:230-239.
47. Hanada K, Furuya K, Yamamoto N, et al. Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biol Pharm Bull 2003; 26:1563-1569.
48. Ng RA, Lanter JC, Alford VC, et al. Synthesis of potent and tissue-selective androgen receptor modulators (SARMs): 2-(2,2,2)-Trifluoroethyl- benzimidazole scaffold. Bioorg Med Chem Lett 2007; 17:1784-1787.
49. Narayanan R, Coss CC, Yepuru M, et al. Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol 2008; 22:2448-2465. This paper showed that DHT and SARMs activate distinct signaling pathways.
50. Masiello D, Chen SY, Xu Y, et al. Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells. Mol Endocrinol 2004; 18:2388-2401.
51. Song LN, Herrell R, Byers S, et al. Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol Cell Biol 2003; 23:1674-1687.
52. Sathya G, Chang CY, Kazmin D, et al. Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion. Cancer Res 2003; 63:8029-8036.
53. Bohl CE, Wu Z, Miller DD, et al. Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. J Biol Chem 2007; 282:13648-13655.
54. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev 2002; 23:175-200.
55. Hamann LG. Discovery and preclinical profile of a highly potent and muscle selective androgen receptor modulator (SARM). 227th National Meeting of the American Chemical Society Medicinal Chemistry Division 2004.
56. Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Ann Rev Biochem 1994; 63:25-61.
57. Sinha-Hikim I, Artaza J, Woodhouse L, et al. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab 2002; 283:E154-E164.
58. Kadi F, Eriksson A, Holmner S, Thornell LE. Effects of anabolic steroids on the muscle cells of strength-trained athletes. Medicine and science in sports and exercise 1999; 31:1528-1534.
59. Hawke TJ, Garry DJ. Myogenic satellite cells: physiology to molecular biology. J Appl Physiol 2001; 91:534-551.
60. Sinha-Hikim I, Roth SM, Lee MI, Bhasin S. Testosterone-induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men. Am J Physiol Endocrinol Metab 2003; 285:E197-E205.
61. Singh R, Artaza JN, Taylor WE, et al. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 2003; 144:5081-5088. This paper was the first to report that androgens regulate myogenic differentiation of mesenchymal multipotent cells.
62. Bhasin S, Taylor WE, Singh R, et al. The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action. J Gerontol A Biol Sci Med Sci 2003; 58:M1103-M1110.
63. Gupta V, Bhasin S, Guo W, et al. Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes. Mol Cell Endocrinol 2008; 296:32-40.
64. Singh R, Artaza JN, Taylor WE, et al. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology 2006; 147:141-154.
65. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men: a clinical research center study. J Clin Endocrinol Metab 1996; 81:3469-3475.
66. Urban RJ, Bodenburg YH, Gilkison C, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995; 269:E820-E826.
67. Ferrando AA, Sheffield-Moore M, Paddon-Jones D, et al. Differential anabolic effects of testosterone and amino acid feeding in older men. J Clin Endocrinol Metab 2003; 88:358-362.
68. Ferrando AA, Sheffield-Moore M, Yeckel CW, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab 2002; 282:E601-E607.
69. Singh R, Bhasin S, Braga M, et al. Regulation of Myogenic Differentiation by Androgens: Cross-Talk between Androgen Receptor/{beta}- Catenin and Follistatin/TGF-{beta} Signaling Pathways. Endocrinology 2009; 150:1259-1268. This paper describes the important role of beta-catenin/Wnt pathway in mediating the effects of testosterone on myogenic differentiation and the role of follistatin in cross-communicating the signal from Wnt to TGFbeta/SMAD pathway.